

# AHCC Trials Group

Newsletter October 2015

The Buzz

## 2<sup>nd</sup> Scientific Forum and 7<sup>th</sup> General Meeting 29 May 2015

### Contents

#### Page 2

##### Happenings

- AHCC Trials Group Scientific Forum and General Meeting, 29 May 2015

#### Page 3

##### Highlights

- AHCC06 Study Status

#### Page 4

##### AHCC Trials Group Secretariat

- AHCC06 Study Status

### AHCC Trials Group

#### Group Chair:

Prof Soo Khee Chee

#### Protocol Chair, AHCC06:

Prof Pierce Chow

#### Trials Group Website:

<http://www.scri.edu.sg/index.php/ahcc-trials-group>

#### Trial Coordinating Centre:



#### Greetings to all members of the AHCC Trials Group!

As we are approaching the last quarter of 2015, the AHCC Trials Group is delighted to share that we have successfully held the 2<sup>nd</sup> Scientific Forum and the 7<sup>th</sup> General Meeting in May this year. Our ongoing AHCC06 SIRveNIB clinical trial has hit more than 90% of its target recruitment and the study team is working to complete recruitment by first quarter of 2016. The Trials Group is also in discussion with academia and pharmaceutical companies on new studies.



Group picture at the AHCC Trials Group General Meeting

1<sup>st</sup> row: Prof Yun Hwan Kim (South Korea/ Korea University Anam Hospital), Prof Tjakra Wibawa Manuaba (Indonesia/ Sanglah General Hospital), Prof Khin Maung Win (Myanmar/ Yangon GI & Liver Centre), Prof Pierce Chow Kah Hoe (Singapore/ Singapore General Hospital), Prof Lesmana (Indonesia/ University of Indonesia), Dr Choo Su Pin (Singapore/ National Cancer Centre), Dr Chee Ean Cheng (Singapore/ National University Hospital)

2<sup>nd</sup> row: Datok Dr Harjit Singh (Malaysia/ Selayang Hospital), Dr James Law (Malaysia/ Sarawak General Hospital), Dr Aung Hlaing Bwa (Myanmar/ Yangon GI & Liver Centre), Assoc Prof Kenneth Kok (Brunei/ Brunei Cancer Centre), Dr Yoong Boon Koon (Malaysia/ University Malaya Medical Center), Dr Cheow Peng Chung (Singapore/ Singapore General Hospital), Dr Chanisa Chotipanich (Thailand/ Chulabhorn Hospital), Ms Lynette Lai (Singapore/ Singapore General Hospital), Ms June Leam Lirong (Singapore/ Singapore Clinical Research Institute), Dr Po-Heng Chuang (Taiwan/ China Medical University Hospital), Dr Frances Tongcos (Philippines/ Davao Doctors Hospital), Mr Xia Yu (Singapore/ Singapore Clinical Research Institute), Ms Sandra Hsing (Singapore/ Singapore Clinical Research Institute), Ms Lim Hui Qing (Singapore/ Singapore Clinical Research Institute), Mr Liew Wei Ming (Singapore/ Singapore Clinical Research Institute)

#### SCIENTIFIC COLLABORATION FOR RESEARCH INNOVATION



## AHCC Trials Group Scientific Forum and General Meeting 29 May 2015, Singapore


The previous Scientific Forum held in October 2014 inspired several potential collaborations between the AHCC Trials Group and external stakeholders. During the latest scientific forum held on 29<sup>th</sup> May 2015, the AHCC Trials Group was proud to present the outcomes of several ongoing studies. These in turn have opened the possibility for more potential studies which were discussed during the General Meeting in the afternoon.

The Asia Pacific Hepatocellular Carcinoma (AHCC) Trials Group Scientific Forum was held at Duke-NUS Graduate Medical School. This forum was open to the general public and more than 100 participants from the Asia Pacific took part in this event. The panel of scientific and clinical speakers shared their extensive research and clinical experience on HCC.

Similar to last year, the Scientific Forum started with Prof Soo Khee Chee giving a welcome address and Prof Pierce Chow, Protocol Chair, AHCC06 giving a short speech on the AHCC Trials Group. Dr Zhai Weiwei, Senior Research Scientist at the Genome Institute of Singapore shared our current research on intratumour heterogeneity and spatial organization. His presentation included some preliminary results from an ongoing study with Prof Pierce Chow. Dr Valerie Chew shared an interesting concept on using the immune microenvironment as a target for therapy for HCC. Dr Ng Ser Sue presented on the relationship between metabolism and liver diseases while Dr Parag Kundu spoke about the gut microbiota liver axis in relation to HCC. Clinical speakers that took part in the scientific program were Dr Yoong Boon Koon from University Malaya Medical Center, Malaysia and Dr Kieron Lim Boon Leng from National University Hospital, Singapore. Dr Yoong shared about the clinical landscape of HCC in Malaysia while Dr Lim gave an update on the recent Expert Meeting on Y90 held in Singapore.

The forum witnessed some interesting discussions after each lecture that engaged speakers and the audience.

In the afternoon, the members of the Trials Group attended the 7<sup>th</sup> General Meeting at the Academia, Singapore General Hospital. The meeting is a closed-door meeting for members only and there were discussions on ongoing studies and proposals for future studies.



*(Left) Prof Pierce Chow (Protocol Chair, AHCC06) gave an update of the AHCC trials Group.*

*(Right) AHCC Trials Group members, Dr James Law, Dr Kenneth Kok, Prof Yun Hwan Kim, Prof Tjakra Wibawa Manuaba, Prof Lesmana, Prof Soo Khee Chee and Dr Kieron Lim at the Scientific Forum.*

## AHCC06 (SIRveNIB)

### Phase III Multi-Centre Open-Label Randomized Control Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma

Protocol Chair: Prof Pierce Chow, NCCS, SGH and Duke-NUS

#### Study Status

As of 30<sup>th</sup> September 2015, 328 patients have been randomized which is 91.1% of the target enrolment. Mr Xia Yu, Project Manager and his team are working very closely with the sites to ensure the recruitment is on track and protocol compliance.

The trial has successfully had its 2<sup>nd</sup> interim analysis on 27 October 2014 and has entered into its last phase of recruitment of the clinical trial. One new site, University Malaya Medical Centre (UMMC), Malaysia was activated this year in January and has since recruited 3 patients. National Cheng Kung University Hospital (NCKUH), Taiwan will be activated in late 2015. With that, the total number of active sites will be 27 and we hope that the recruitment will end by first quarter of 2016.

The trial has also received an additional grant from the National Medical Research Council (NMRC) on top of the additional funding of \$1.9 million from Sirtex. These additional funding will cover most of the trial related expenses which were previously not covered and these benefit patients who previously could not afford the investigations required in the protocol.

The study team thanks all the sites for their hard work and support.

For more details on the AHCC06 trial, please visit <http://www.sirvenib.com/>

#### Participating Centres:

##### Brunei

- The Brunei Cancer Centre

##### Indonesia

- University of Indonesia  
- Sanglah General Hospital

##### Korea

- Asan Medical Center  
- Korea Anam University Hospital  
- Seoul National University Hospital  
- Seoul St. Mary's Hospital  
- Severance Hospital, Yonsei

##### Malaysia

- Penang Adventist Hospital  
- Sarawak General Hospital  
- University Malaya Medical Centre

##### Mongolia

- National Cancer Center

##### Myanmar

- Yangon GI & Liver Centre

##### New Zealand

- Auckland City Hospital

##### Philippines

- Makati Medical Center  
- St. Luke's Medical Center  
- The Medical City  
- Davao Doctors Hospital

##### Singapore

- Khoo Teck Puat Hospital  
- National Cancer Centre  
- National University Hospital  
- Singapore General Hospital

##### Taiwan

- National Taiwan University Hospital  
- Chang Gung Memorial Hospital, LK  
- Taipei Veterans General Hospital  
- China Medical University Hospital  
- National Cheng Kung University Hospital (to be activated in September 2015)

##### Thailand

- Chulabhorn Hospital



Prof Chow and the Taiwanese Investigators met in Taipei, Taiwan in June 2015.

## The AHCC Trials Group Secretariat



From left, Mr Goh Zhaohan, Mr Win Oo Htut, Ms Fiona Ni Ni Moe, Prof Pierce Chow (Protocol Chair, AHCC06), Ms Liang Ai Leng, Ms Lynette Lai, Ms Rachel Choi and Ms Phang Su Ting

Since the conception of the AHCC Trials Group in 1997, the AHCC Trials Group Secretariat led by Prof Pierce Chow has been involved in the general administration and management of the AHCC Trials Group network. The Secretariat has been maintaining the network registry, website, social media sites and the publishing of the periodic newsletter for the network to keep the group abreast of any developments and happenings across the network. The Secretariat works closely with academic clinical trials organizations, pharmaceutical and biotech industry partners to organize the General Meetings, Scientific Forum as well as ad hoc meetings of the trials group.

### Contact Details

For further queries, please contact the AHCC Trials Group at

Project Manager (AHCC06):

*Mr Xia Yu*

Email: [yu.xia@scri.edu.sg](mailto:yu.xia@scri.edu.sg)

DID: (65) 6508 8314

Network Secretariat:

*Ms Lynette Lai*

Email: [lynette.lai.s.h@sqh.com.sg](mailto:lynette.lai.s.h@sqh.com.sg) / [ahcctrialsgroup@nccs.com.sg](mailto:ahcctrialsgroup@nccs.com.sg)

DID: (65) 6326 2151

*Ms Phang Su Ting*

Email: [phang.su.ting@sqh.com.sg](mailto:phang.su.ting@sqh.com.sg)

DID: (65) 6576 6450

*Ms Rachel Choi*

Email: [rachel.choi.h.y@sqh.com.sg](mailto:rachel.choi.h.y@sqh.com.sg)

DID: (65) 6576 7657

Read more about all trials  
under AHCC Trials Group at  
<http://www.scri.edu.sg>.

Mailing Address: 31 Biopolis Way Nanos #02-01 Singapore 138669

Acknowledgements: National Medical Research Council Singapore, SingHealth Foundation, PsiOncology, Sirtex Medical and Bayer Pharmaceutical for support of our clinical trials, past and present.